Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines

Oncogene

Volumn 28, Issue 35, 2009, Pages 3121-3131

  Swartling, F J ^a,b   Ferletta, M ^b   Kastemar, M ^b   Weiss, W A ^a   Westermark, B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Akt; CGMP dependent protein kinase II; Glioma; PDGF; Sox9; VASP

Indexed keywords

8 (4 CHLOROPHENYLTHIO) CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE 2; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXPRESSION VECTOR; GENETIC TRANSFECTION; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

CELL ADHESION; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, SERUM-FREE; CYCLIC GMP-DEPENDENT PROTEIN KINASES; GENETIC VECTORS; GLIOMA; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RETROVIRIDAE; SOX9 TRANSCRIPTION FACTOR; TIME FACTORS; TRANSFECTION;

MOLONEY MURINE LEUKEMIA VIRUS;

EID: 69849089410     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.168     Document Type: Article

References (43)

1. Butt E, Abel K, Krieger M, Palm D, Hoppe V, Hoppe J et al. (1994). cAMP-and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J Biol Chem 269: 14509-14517.
2. Cen B, Deguchi A, Weinstein IB. (2008). Activation of protein kinase G increases the expression of p21CIP1, p27KIP1, and histidine triad protein 1 through Sp1. Cancer Res 68: 5355-5362.
3. Chen L, Daum G, Chitaley K, Coats SA, Bowen-Pope DF, Eigenthaler M et al. (2004). Vasodilator-stimulated phosphoprotein regulates proliferation and growth inhibition by nitric oxide in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 24: 1403-1408.
4. Cheung M, Briscoe J. (2003). Neural crest development is regulated by the transcription factor Sox9. Development 130: 5681-5693.
5. Chikuda H, Kugimiya F, Hoshi K, Ikeda T, Ogasawara T, Shimoaka T et al. (2004). Cyclic GMP-dependent protein kinase II is a molecular switch from proliferation to hypertrophic differentiation of chondrocytes. Genes Dev 18: 2418-2429.
6. Cook AL, Haynes JM. (2004). Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal 16: 253-261.
7. Deguchi A, Thompson WJ, Weinstein IB. (2004). Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. Cancer Res 64: 3966-3973.
8. Dromard C, Bartolami S, Deleyrolle L, Takebayashi H, Ripoll C, Simonneau L et al. (2007). NG2 and Olig2 expression provides evidence for phenotypic deregulation of cultured central nervous system and peripheral nervous system neural precursor cells. Stem Cells 25: 340-353.
9. Finzsch M, Stolt CC, Lommes P, Wegner M. (2008). Sox9 and Sox10 influence survival and migration of oligodendrocyte precursors in the spinal cord by regulating PDGF receptor alpha expression. Development 135: 637-646.
10. Gambaryan S, Palmetshofer A, Glazova M, Smolenski A, Kristjans-son GI, Zimmer M et al. (2002). Inhibition of cGMP-dependent protein kinase II by its own splice isoform. Biochem Biophys Res Commun 293: 1438-1444.
11. Gudi T, Hong GK, Vaandrager AB, Lohmann SM, Pilz RB. (1999). Nitric oxide and cGMP regulate gene expression in neuronal and glial cells by activating type II cGMP-dependent protein kinase. FASEB J 13: 2143-2152.
12. Guha A, Dashner K, Black PM, Wagner JA, Stiles CD. (1995). Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 60: 168-173.
13. Hagerstrand D, Hesselager G, Achterberg S, Wickenberg Bolin U, Kowanetz M, Kastemar M et al. (2006). Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene 25: 4913-4922.
14. Hofmann F, Feil R, Kleppisch T, Schlossmann J. (2006). Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev 86: 1-23.
15. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. (2000). Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25: 55-57.
16. Hou Y, Gupta N, Schoenlein P, Wong E, Martindale R, Ganapathy V et al. (2006). An anti-tumor role for cGMP-dependent protein kinase. Cancer Lett 240: 60-68. (Pubitemid 44037177)
17. Humphrey PA, Wong AJ, Vogelstein B, Friedman HS, Werner MH, Bigner DD et al. (1988). Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48: 2231-2238.
18. Johansson FK, Brodd J, Eklof C, Ferletta M, Hesselager G, Tiger CF et al. (2004). Identification of candidate cancer-causing genes in mouse brain tumors by retroviral tagging. Proc Natl Acad Sci USA 101: 11334-11337.
19. Johansson FK, Goransson H, Westermark B. (2005). Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice. Oncogene 24: 3896-3905.
20. Johansson Swartling F. (2008). Identifying candidate genes involved in brain tumor formation. Ups J Med Sci 113: 1-38.
21. Kordes U, Hagel C. (2006). Expression of SOX9 and SOX10 in central neuroepithelial tumor. J Neurooncol 80: 151-155.
22. Lahortiga I, Akin C, Cools J, Wilson TM, Mentens N, Arthur DC et al. (2008). Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 93: 49-56.
23. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
24. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H et al. (1985). Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144-147.
25. Nister M, Libermann TA, Betsholtz C, Pettersson M, Claesson-Welsh L, Heldin CH et al. (1988). Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res 48: 3910-3918.
26. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
27. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al. (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173.
28. Smolenski A, Burkhardt AM, Eigenthaler M, Butt E, Gambaryan S, Lohmann SM et al. (1998). Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects. Naunyn Schmiedebergs Arch Pharmacol 358: 134-139.
29. Smolenski A, Poller W, Walter U, Lohmann SM. (2000). Regulation of human endothelial cell focal adhesion sites and migration by cGMP-dependent protein kinase I. J Biol Chem 275: 25723-25732. (Pubitemid 30687076)
30. Sottile V, Li M, Scotting PJ. (2006). Stem cell marker expression in the Bergmann glia population of the adult mouse brain. Brain Res 1099: 8-17.
31. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23. 3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362.
32. Stolt CC, Lommes P, Sock E, Chaboissier MC, Schedl A, Wegner M. (2003). The Sox9 transcription factor determines glial fate choice in the developing spinal cord. Genes Dev 17: 1677-1689.
33. Tanaka J, Markerink-van Ittersum M, Steinbusch HW, De Vente J. (1997). Nitric oxide-mediated cGMP synthesis in oligodendrocytes in the developing rat brain. Glia 19: 286-297.
34. Taylor MK, Ahmed R, Begley M, Uhler MD. (2002). Autoinhibition and isoform-specific dominant negative inhibition of the type II cGMP-dependent protein kinase. J Biol Chem 277: 37242-37253.
35. Uhrbom L, Hesselager G, Nister M, Westermark B. (1998). Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 58: 5275-5279.
36. Villalobo A. (2006). Nitric oxide and cell proliferation. FEBS J 273: 2329-2344.
37. Vindelov LL, Christensen IJ, Nissen NI. (1983). A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327.
38. Walz C, Metzgeroth G, Haferlach C, Schmitt-Graeff A, Fabarius A, Hagen V et al. (2007). Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica 92: 163-169.
39. Wang H, Leav I, Ibaragi S, Wegner M, Hu GF, Lu ML et al. (2008). SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res 68: 1625-1630.
40. Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan X. (2007). SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res 67: 528-536.
41. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D et al. (1997). Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57: 4183-4186.
42. Yin D, Wang X, Konda BM, Ong JM, Hu J, Sacapano MR et al. (2008). Increase in brain tumor permeability in glioma-bearing rats with nitric oxide donors. Clin Cancer Res 14: 4002-4009.
43. Yoshioka A, Yamaya Y, Saiki S, Kanemoto M, Hirose G, Pleasure D. (2000). Cyclic GMP/cyclic GMP-dependent protein kinase system prevents excitotoxicity in an immortalized oligodendroglial cell line. J Neurochem 74: 633-640.